{
    "clinical_study": {
        "@rank": "21614", 
        "acronym": "OM-174", 
        "brief_summary": {
            "textblock": "Methods Patients received OM-174 twice weekly for a total of 5, 10 or 15 injections of\n      either 600, 800 or 1000 \u00b5g/m\u00b2. Pharmacokinetic analysis and cytokine dosages were performed.\n      Natural Killer cells activity and toll-like receptors 4 polymorphism analysis were also\n      performed."
        }, 
        "brief_title": "Effects of OM-174 in Adult Patients With Solid Tumors", 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with a histologically proven solid tumor, refractory to conventional\n             treatment or for which no such treatment existed.\n\n          -  At least one month since the last chemotherapy\n\n          -  Life expectancy above 3 months\n\n          -  Written informed consent\n\n          -  Age above 18\n\n        Exclusion Criteria:\n\n          -  Patient's refusal\n\n          -  Infection\n\n          -  Brain metastasis\n\n          -  Autoimmune disease\n\n          -  Regular use of steroids\n\n          -  Patient included in another protocol\n\n          -  Chemotherapy or radiotherapy less than 6 weeks ago\n\n          -  Immunotherapy less than 8 weeks ago"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "27", 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800812", 
            "org_study_id": "BARDOU PHRC R 2002"
        }, 
        "intervention": {
            "intervention_name": "Injections of OM-174", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 26, 2013", 
        "official_title": "Phase One Study With Direct Individual Benefit: Effects of OM-174 in Adult Patients With Solid Tumors.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The occurrence of any adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800812"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Centre Hospitalier Universitaire Dijon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Dijon", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2007", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}